PER® Winter Lung Cancer Conference | Conference

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

February 3rd 2025

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research

February 2nd 2025

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy

February 2nd 2025

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer

February 1st 2025

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

February 1st 2025

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

February 7th 2024

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

February 7th 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

February 6th 2024

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

February 6th 2024

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

February 6th 2024

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations

February 6th 2024

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

February 4th 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

Dr Curran on Developing Strategies for Stage III NSCLC Management

February 4th 2024

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.